Кардиологические осложнения акромегалии


Цитировать

Полный текст

Аннотация

Частым осложнением акромегалии у пациентов любого возраста является акромегалическая кардиомиопатия, для которой характерно формирование гипертрофии миокарда левого желудочка (ГМЛЖ), возникновение нарушений сердечного ритма. В случаях, когда гормональные нарушения при акромегалии остаются без адекватного контроля, кардиомиопатия приводит к формированию диастолической сердечной недостаточности. Хирургическое и медикаментозное (с помощью аналогов соматостатина) лечение акромегалии приводит к улучшению состояния сердца и регрессу ГМЛЖ, особенно у молодых пациентов (моложе 40 лет) с небольшой длительностью заболевания (не более 5 лет). Значимое улучшение морфо-функциональных и гемодинамических параметров отмечается и у пациентов среднего возраста.

Об авторах

И А Иловайская

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

ФГУ Эндокринологический научный центр Росмедтехнологий, Москва

I A Ilovayskaya

Список литературы

  1. 1. Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol 2001; 54:137-154.
  2. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2008;69(3):347-358.
  3. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89(2):667-674.
  4. Huchard H. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acromegalie. J Practiciens 1895;9:249-250.
  5. Minniti G, Jaffrain-Rea ML, Moroni C, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol 1998;49:101-106.
  6. Fazio S, Cittadini A, Sabatini D, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J 1993;14:26-33.
  7. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999;341: 1276-1283.
  8. Белова Ю.Ю., Марова Е.И., Шамарин В.М. и др. Патология сердечно-сосудистой системы при акромегалии // Проблемы эндокринологии. <http://ucm.sibtechcenter.ru/?query=rec.id%3D%22%D0%9F230180%22&sortKeys=none&startRecord=1&maximumRecords=5&recordSchema=marcxml&recordPacking=xml&mode=standard> 2004. -Т. 50. № 2. С. 3947 <http://ucm.sibtechcenter.ru/?query=rec.id%3D%22%D0%9F230180%2F2004%2F50%2F2%22&sortKeys=none&startRecord=1&maximumRecords=5&recordSchema=marcxml&recordPacking=xml&mode=standard>.
  9. Colao A, Ferone D, Marzullo P, et al. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews 2004;25(1):102-152.
  10. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 1980;100:41-52.
  11. Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000;85:179-182.
  12. Colao A, Spinelli L, Cuocolo A, et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 2002;87:3097-3104.
  13. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000;85:193-199.
  14. López-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997;82:1047-1053.
  15. Ferrari AU. Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol 2002;11:30-33.
  16. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;13:51-56.
  17. Cable DG, Dearani JA, O'Brien T, et al. Surgical treatment of valvular heart disease in patients with acromegaly. J Heart Valve Dis 2000;9:828-831.
  18. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational analytical prospective case-control study. J Clin Endocrinol Metab 2003;88:3196-3201.
  19. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 1995;30:825-834.
  20. Wahlander H, Isgaard J, Jennische E, et al. Left ventricular insulin-like growth factor-I increases in early renal hypertension. Hypertension 1992;19:25-32.
  21. Cittadini A, Stromer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800-809.
  22. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol Cell Biochem 1996;163:223-229.
  23. Frustaci A, Chimenti C, Setoguchi M, et al. Cell death in acromegalic cardiomyopathy. Circulation 1999;99:1426-1434.
  24. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
  25. Gatford KL, Egan AR, Clarke IJ, et al. Sexual dimorphism of the somatotrophic axis. J Endocrinol 1998;157:373-389.
  26. Parkinson C, Renehan AG, Ryder WD, et al. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol 2002;57:59-64.
  27. Colao A, Cuocolo A, Marzullo P, et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. J Clin Endocrinol Metab 1999;84:1518-1523.
  28. Boero L <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Boero%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Manavela M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Manavela%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Rosso LG <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rosso%20LG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');> 2009;70(1): 88-95.
  29. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992;13:51-56.
  30. Kozer LM, Cheriparambil KM, Schifter DR, et al. Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction. Am Heart J 2000;139:134-141.
  31. Herrmann BL, Bruch C, Saller B, et al. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol 2001;55:201-207.
  32. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001;15:601-605.
  33. Jaffrain-Rea ML, Moroni C, Baldelli R, et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol 2001;54:189-195.
  34. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Terzolo M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Terzolo%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Bondanelli M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bondanelli%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2008;69(4):613-20.
  35. Ritchie CM, Sheridan B, Fraser R, et al. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q J Med 1990;76:855-867.
  36. Chanson P, Megnien JL, del Pino M, et al. Decreased regional blood flow in patients with acromegaly. Clin Endocrinol 1998;49:725-731.
  37. Deray G, Chanson P, Maistre G, et al. Atrial natriuretic factor in patients with acromegaly. Eur J Clin Pharmacol 1990;38:409-413.
  38. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-299.
  39. Swearingen B, Barker FGII, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.
  40. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol 2001;55:307-313.
  41. Colao A, Cuocolo A, Marzullo P, et al. Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 2001;86: 1551-1557.
  42. Tokgözoglu SL, Erbas T, Aytemir K, et al. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994;74:1072-1074.
  43. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;77: 790-793.
  44. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990;113: 921-925.
  45. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;86: 3132-3140.
  46. Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol 2003;58: 169-176.
  47. Maison P <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Maison%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Tropeano AI <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tropeano%20AI%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Macquin-Mavier I <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Macquin-Mavier%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Endocrinol%20Metab.');> 2007;92(5):1743-1747.
  48. Damjanovic SS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Damjanovic%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Neskovic AN <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Neskovic%20AN%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Petakov MS <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Petakov%20MS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol <javascript:AL_get(this,%20'jour',%20'Clin%20Endocrinol%20(Oxf).');>2005;62(4):410-417.
  49. Colao A <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Colao%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Pivonello R <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pivonello%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, Galderisi M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Galderisi%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab <javascript:AL_get(this,%20'jour',%20'J%20Clin%20Endocrinol%20Metab.');> 2008;93(7):2639-2646.
  50. Lombardi G, Colao A, Marzullo P, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced growth hormone and insulin-like growth factor-I decrease in acromegaly: a prospective multicenter study. J Endocrinol Invest 2002;25:971-976.
  51. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2321&mid=1085056570&magid=174&full=1

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2009